1. Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy
- Author
-
Chia-Hui Chu, Ren-Chin Wu, Wen-Chi Shen, Shin-Cheh Chen, Wen-Lin Kuo, Chi-Chang Yu, Shir-Hwa Ueng, Hsiu-Pei Tsai, Shih-Che Shen, Yung-Chang Lin, Yung-Feng Lo, Hsien-Kun Chang, Yi-Ting Huang, and Hsu-Huan Chou
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,intrinsic subtype ,business.industry ,medicine.medical_treatment ,medicine.disease ,Lower risk ,pathologic complete response ,breast cancer ,Breast cancer ,Internal medicine ,medicine ,Overall survival ,Human epidermal growth factor receptor ,business ,Complete response ,Research Paper ,neoadjuvant chemotherapy ,Early breast cancer ,Hormone - Abstract
Few studies have analyzed the discrepancy between breast pathologic complete response (B-pCR) and axillary node pCR (N-pCR) rates and their impact on survival outcomes in different intrinsic subtypes of early breast cancer after neoadjuvant chemotherapy (NAC). We retrospectively reviewed B-pCR, N-pCR, and total (breast and axillary node) pCR (T-pCR) after NAC to assess the discrepancy and outcomes between 2005 and 2017. A total of 968 patients diagnosed with cT1-4c, N1-2, and M0 breast cancer were enrolled in the study. The median age was 49 years and the median follow-up time was 45 months. Of these patients, 213 achieved T-pCR, 31 achieved B-pCR with axillary node pathologic non-complete response (N-non pCR), 245 achieved N-pCR with breast pathologic non-complete response (B-non pCR), and 479 achieved total (breast and axillary node) pathologic non-complete response (T-non pCR) after NAC. The highest B-pCR and N-pCR rates were found in the hormone receptor-negative, human epidermal growth factor receptor 2-positive HR(-)HER2(+) subtype, while the lowest B-pCR rate was found in the HR(+)HER2(-) subtype. The N-pCR rate was correlated to the B-pCR rate (P
- Published
- 2021